TRATTAMENTO DELLE INFEZIONI NELL’EVAR · Elio Piccinini U.O.C. Chirurgia Vascolare ed...
Transcript of TRATTAMENTO DELLE INFEZIONI NELL’EVAR · Elio Piccinini U.O.C. Chirurgia Vascolare ed...
Elio PiccininiU.O.C. Chirurgia Vascolare ed Endovascolare Ravenna
AUSL Romagna
SIMPOSIO EVAR – RER
TRATTAMENTO DELLE INFEZIONI NELL’EVAR
“ Quando colui che ascolta non capisce colui che parla , e colui che parla non sa cosa sta dicendo :
questa è filosofia “.
#2 . AAA #3 .INFEZIONE
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
#1 . EVAR #4 . RER / AUSL
SIMPOSIO EVAR – RER
“ Quando colui che ascolta non
capisce colui che parla , e colui
che parla non sa cosa sta dicendo
:
questa è filosofia “.
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
#1 . EVAR
SIMPOSIO EVAR – RER
ARGYRIOU 2017 0.6%
MAEFISTO 2016 3.9 %
“ Remote Endoprosthetic Repair ”( R.E.R.)
Volodos 1985
T.EVAR , F.EVAR , B.EVAR , ch.EVAR , R.EVAR , P.EVAR , EVA.S , ch.EVAS …
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
#1 . EVAR
SIMPOSIO EVAR – RER
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
#1 . EVAR
SIMPOSIO EVAR – RER
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
SIMPOSIO EVAR – RER
INFETTO
• 1885 W. Osler
• 2014 – 2016 - 2017 K Sorelius
#2 . AAA
SOSPETTO
• 2016 M.A.G..IC.
• 2016 M.A.E.F.I.S.T.O.
NON INFETTO
• 2003 Marques da Silva
• 2007 Human Microbiome
• 2015 Vascular Microbiome
• 2016 Capnocytophaga canimorsus
#2 . AAA
“… it may be presumed that ….the larger sac presented a condition of mycotic
endarteritis unique in my experience of aortic aneurysms.”
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
SIMPOSIO EVAR – RER
THE GULSTONIAN LECTURES
ON
ENDOCARDITIS
Delivered at the Royal College of Physicians of London , march ,
1885
By WILLIAM OSLER M.D.
1. Osler W. Malignant endocarditis: lecture I. Lancet. March 7
,1885;1:467– 470.
2. Osler W. Malignant endocarditis: lecture II. Lancet. March 14
,1885;1:522 –526
3. Osler W. Malignant endocarditis: lecture III. Lancet. March 21
,1885;1:577 –579
1. Sörelius K, Mani K, Björck M, Sedivy P, Wahlgren CM, Taylor P, Clough RE, Lyons O,
Thompson M, Brownrigg J, Ivancev K, Davis M, Jenkins MP, Jaffer U, Bown M, Rancic Z,
Mayer D, Brunkwall J, Gawenda M, Kölbel T, Jean-Baptiste E, Moll F, Berger P, Liapis CD,
Moulakakis KG, Langenskiöld M, Roos H, Larzon T, Pirouzram A , Wanhainen A;
European MAA collaborators. Endovascular treatment of mycotic aortic aneurysms:
a European multicenter study.
Circulation. 2014 Dec 9;130(24):2136-42.
2. Sörelius K, Wanhainen A, Furebring M, Björck M, Gillgren P, Mani K; Swedish Collaborator Group for Mycotic Abdominal
Aortic Aneurysms*.
Nationwide Study of the Treatment of Mycotic Abdominal Aortic Aneurysms Comparing Open and Endovascular
Repair.
Circulation. 2016 Dec 6;134(23):1822-1832.
3. Sörelius K, Mani K, Björck M, Wanhainen A.
Endovascular treatment of mycotic aortic aneurysms: a paradigm shift.
J Cardiovasc Surg (Torino). 2017 Dec;58(6):870-874.
Conclusion
Endovascular treatment of MAA is feasible and for most patients a durable treatment option. Late infection–
related complications do occur, are often lethal, and warrant longterm antibiotic treatment and follow-up,
especially in patient with non-Salmonella–positive blood culture. In those cases, EVAR could be
considered a palliative option or a bridge to later elective open repair.
Conclusion
Although the role of EVAR for MAAA has been questioned because of the perceived risk of reinfection, the
present study indicates that EVAR for MAAA is associated with better short-term survival in comparison with
OR, and comparable long-term results in terms of survival and infectionrelated complications or reinterventions.
In Sweden, EVAR has been the primary surgical technique used for MAAAs in recent years, and data suggest
that more patients are being offered treatment after the introduction of EVAR.
On the basis of the results of the present cohort study, it seems justified to regard EVAR as an
acceptable alternativeto traditional OR for the treatment of MAAAs.
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
“ There is no universally accepted aortic graft infection case definition”
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
2016
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
2016
Aortic graft infection (AGI) is :
•suspected in a patient with
any isolated major criterion,
or
minor criteria from two of the three categories
•diagnosed in the presence of
a single major criterion,
plus
any other criterion (major or minor) from another category.
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
2016
Aortic graft infection (AGI) is :
•suspected in a patient with
any isolated major criterion,
or
minor criteria from two of the three
categories
•diagnosed in the presence of
a single major criterion,
plus
any other criterion (major or minor)
from another category.
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
“ Thus it may be concluded that aortic aneurysms contain bacteria.
However, the presence of bacteria in aortic aneurysms does not necessarily imply a causal
relationship, and some organisms may actually be secondary colonizers after aneurysm formation.
In any case, it is unlikely that viable and multiplying organisms detected inside the aneurysm wall
tissue are harmless “.
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
Curr Opin Rheumatol 2015, 27 : 397 - 405
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
2017
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
MRSA
MDRO
BACTERIA PHYLUM CLASSE ORDINE FAMIGLIA GENERE SPECIE
ENTEROBACTERIALES -ENTEROBACTERIACEAE
KLEBSIELLA - K. PNEUMONIAE
ESCHERICHIA - E. COLI
MORAXELLACEAE - ACINETOBACTER - A. BAUMANII
PSEUDOMONADACEAE - PSEUDOMONAS- P. AERUGINOSA
PSEUDOMONADALES
CPE
BACTERIA - PROTEOBACTERIA - GAMMAPROTEOBACTERIA
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
3. INFEZIONE
1974 Finseth-Abbott
2016 Human Microbiome Map
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
MRSA
MDRO
CPE
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
ANN VASC SURG 2016
#3 .INFEZIONE
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
SIMPOSIO EVAR – RER
A WOLF IN SHEEP’S CLOTHING
#3 .INFEZIONE
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
#3 .INFEZIONE
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
#4 . RER / AUSL
SIMPOSIO EVAR – RER
2016 LINEE GUIDA RER PER FLUSSO SICHER
CATEGORIE DI INTERVENTO E RELATIVI CODICI ICD9-CN
1.AAA Riparazione di aneurisma aortico 38.34,38.44,38.64
2. Durata della sorveglianza : 90 giorni se e’ stato utilizzato
materiale protesico
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
SIMPOSIO EVAR – RER
#4 . RER / AUSL
MRSA CPE
1. EVAR
2. AAA :
• INFETTO
1885 W. Osler
2014-16-17 K Sorelius
• SOSPETTO
2016 M.A.G..IC.
2016 M.A.E.F.I.S.T.O.
• NON INFETTO
2003 Marques da Silva
2007 Human Microbiome
2015 Vascular Microbiome
2016 Capnocytophaga canimorsus
3. INFEZIONE
1974 Finseth-Abbott
2013 Wolf in Shepp’s Clothing
4. RER
2017 SICHER
2017 AUSL.Romagna
5. TRATTAMENTO DELLE
INFEZIONI NELL ’ EVAR
SIMPOSIO EVAR – RER
#4 . RER / AUSL
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
ARGYRIOU 2017 0.6% vs MAEFISTO 2016 3.9 %
2016
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
2016
Algorithm for intraabdominal
vascular graft infection
management
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
NOT
REPORTED
59
NO
TREATMENT
1
CONSERVATIVE
TREATMENT
9
IN SITU
RECONSTRUCTION
233
ENDOVASCULAR
TREATMENT
2
PATIENTS
362
EXTRA-ANATOMICAL
BYPASS
58
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
Fatima J, Duncan AA, de
Grandis E, Oderich GS,
Kalra M, Gloviczki P, et al.
Treatment strategies and
outcomes in patients with
infected aortic endografts.
J Vasc Surg2013;58:371-9.
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM
DOMANDE:
1. INCIDENZA ?
2. REGOLE ?
2016 AHA SCIENTIFIC STATEMENT
3. EVIDENZE ?
2017 ARGYRIOU
SYSTEMATIC REVIEW
/META-ANALYSIS
4. ALGORITMI OPERATIVI ?
2016 SMEDS
VASCULAR LOW-FREQUENCY
DISEASE CONSORTIUM